How long does it take to safely stop taking Bikeren Prenol Tablets (Bituvi) and reference for the medication cycle?

Biktarvy is a combination antiviral oral tablet indicated for the long-term treatment of HIV-1 infection. Typically, the goal of Biktarvy is to achieve and maintain an undetectable viral load to reduce immune impairment and the risk of opportunistic infections. Since HIV infection is a chronic and persistent disease, and there is currently no complete cure, Biktarvy is not a drug that can be taken for a short period of time and then discontinued. Long-term and regular use is an important prerequisite to ensure the safety and efficacy of treatment.

In clinical practice, patients usually need to continue taking the drug for weeks to months after starting Biktarvy treatment to reach an undetectable viral load. Generally speaking, by taking medications regularly and having doctors regularly monitor viral load and CD4 cell count, the patient's viral level can be stably controlled at a low level and the immune function can gradually recover. In the early stages of treatment, doctors will develop an individualized treatment plan based on the patient's basic viral load, immune status, and comorbidities, and closely monitor hematological indicators and liver and kidney functions.

Regarding the issue of safe discontinuation of medication, current guidelines recommend that Biktarvy should not be discontinued on your own. Unauthorized discontinuation of medication may lead to viral rebound, emergence of drug-resistant mutations, and even increased risk of opportunistic infections. Discontinuation or replacement of the regimen must be carried out under the guidance of a professional doctor. It is usually necessary to first assess the patient's viral load stability, immune function and potential comorbidities, and at the same time develop an alternative treatment or transition plan to ensure that the viral suppression effect is not broken. If the drug must be discontinued due to drug intolerance or special medical reasons, doctors will conduct strict clinical evaluation and monitoring, and if necessary, adopt a combination antiviral regimen to reduce the risk.

In general, Biktarvy ’s medication cycle should be aimed at maintaining long-term viral suppression, and there is no fixed “safe discontinuation” time point. Patients need to take medicine regularly for a long time under the guidance of professional doctors, and regularly review viral load, CD4 count, liver and kidney function and other indicators. Through scientific management and continuous monitoring, we can maximize the therapeutic effect of Biktarvy while ensuring safety, reduce the risk of drug resistance and viral rebound, and achieve long-term HIV management and health maintenance.

Reference materials:https://www.nlm.nih.gov/